Artemisinin and Derivatives Market to Reach $200 Million by 2025, Driven by Expanded Malaria Eradication Programs and Emerging Therapeutic Applications The global Artemisinin and Derivatives Market is ...

Novartis has won approval in Switzerland for the world’s first malaria drug for newborns and infants, creating a new weapon ...

The declaration of Suriname as the first malaria-free Amazonian country by the World Health Organization should spur other ...

Novartis and the non-profit Medicines for Malaria Venture (MMV) have advanced a novel drug combination for malaria into a phase 3 programme, raising hopes of a regimen that could be used to treat ...

Bookmark stories for easy access on any device or the Swarajya app. Traditional and Modern Medicine Can and Must Co-exist. As modern medicine struggles with chronic illness and rising costs ...

According to the World Health Organisation (WHO), malaria prevalence declined from 14 percent in 2015 to 8.1 percent in 2022. However, the disease continues to affect some regions significantly and ...

Malaria is a mosquito-borne disease that is caused by Plasmodium parasites. Patients with malaria experience flu-like symptoms and, in severe cases, the disease can progress to neurological ...

Engineering strategies to improve terpenoids’ production in Bacillus subtilis mainly focus on 2C-methyl-d-erythritol-4-phosphate (MEP) pathway overexpression. To systematically engineer the chassis ...